BACKGROUND: Genetic polymorphisms in combination with the Western-style diet, physical inactivity, smoking, excessive alcohol consumption, and obesity have been hypothesized to affect colorectal cancer (CRC) risk. Metabolizers of environmental carcinogenic and endogenous compounds affecting CRC risk include the phase II detoxification UDP-glucuronosyltransferase (UGT) enzymes UGT2B17 and UGT2B28, which are 2 of the most commonly deleted genes in the genome. METHODS: To study the effect of UGT2B17 and UGT2B28 copy number variation (CNV) on CRC risk, 665 Caucasian CRC cases and 621 Caucasian controls were genotyped who had completed extensive demographics and lifestyle questionnaires. RESULTS: A significant association between the UGT2B17 deletion genotype (0/0) and decreased CRC risk was found when the entire population was analyzed (P = .044). Stratification by sex yielded a decreased risk (P = .020) in men with the UGT2B17 deletion (0/0), but no association was observed in women (P = .724). A significant association between UGT2B17 (0/0) and decreased risk for rectal (P = .0065) but not colon cancer was found. No significant association was found between UGT2B28 CNV and CRC risk. CONCLUSIONS: The UGT2B17 deletion genotype (0/0) was associated with a decreased CRC risk in a Caucasian population. After sex stratification, the association was observed in men but not in women, which is consistent with previous findings that men have higher UGT2B17 expression and activity than women. Because UGT2B17 metabolizes certain nonsteroidal anti-inflammatory drugs and flavonoids with antioxidative properties, individuals with a gene deletion may have higher levels of these protective dietary components.
BACKGROUND: Genetic polymorphisms in combination with the Western-style diet, physical inactivity, smoking, excessive alcohol consumption, and obesity have been hypothesized to affect colorectal cancer (CRC) risk. Metabolizers of environmental carcinogenic and endogenous compounds affecting CRC risk include the phase II detoxification UDP-glucuronosyltransferase (UGT) enzymes UGT2B17 and UGT2B28, which are 2 of the most commonly deleted genes in the genome. METHODS: To study the effect of UGT2B17 and UGT2B28 copy number variation (CNV) on CRC risk, 665 Caucasian CRC cases and 621 Caucasian controls were genotyped who had completed extensive demographics and lifestyle questionnaires. RESULTS: A significant association between the UGT2B17 deletion genotype (0/0) and decreased CRC risk was found when the entire population was analyzed (P = .044). Stratification by sex yielded a decreased risk (P = .020) in men with the UGT2B17 deletion (0/0), but no association was observed in women (P = .724). A significant association between UGT2B17 (0/0) and decreased risk for rectal (P = .0065) but not colon cancer was found. No significant association was found between UGT2B28 CNV and CRC risk. CONCLUSIONS: The UGT2B17 deletion genotype (0/0) was associated with a decreased CRC risk in a Caucasian population. After sex stratification, the association was observed in men but not in women, which is consistent with previous findings that men have higher UGT2B17 expression and activity than women. Because UGT2B17 metabolizes certain nonsteroidal anti-inflammatory drugs and flavonoids with antioxidative properties, individuals with a gene deletion may have higher levels of these protective dietary components.
Authors: Nina Joshi; Laura Lee Johnson; Wen-Qiang Wei; Christian C Abnet; Zhi-Wei Dong; Philip R Taylor; Paul J Limburg; Sanford M Dawsey; Ernest T Hawk; You-Lin Qiao; Ilan R Kirsch Journal: Cancer Res Date: 2006-07-01 Impact factor: 12.701
Authors: Frances E Thompson; Amy F Subar; Charles C Brown; Albert F Smith; Carolyn O Sharbaugh; Jared B Jobe; Beth Mittl; James T Gibson; Regina G Ziegler Journal: J Am Diet Assoc Date: 2002-02
Authors: Sujata Bhoi; Panagiotis Baliakas; Diego Cortese; Mattias Mattsson; Marie Engvall; Karin E Smedby; Gunnar Juliusson; Lesley-Ann Sutton; Larry Mansouri Journal: Haematologica Date: 2015-11-20 Impact factor: 9.941
Authors: Dominique Scherer; Lisel M Koepl; Elizabeth M Poole; Yesilda Balavarca; Liren Xiao; John A Baron; Li Hsu; Anna E Coghill; Peter T Campbell; Sarah E Kleinstein; Jane C Figueiredo; Johanna W Lampe; Katharina Buck; John D Potter; Richard J Kulmacz; Mark A Jenkins; John L Hopper; Aung K Win; Polly A Newcomb; Cornelia M Ulrich; Karen W Makar Journal: Genes Chromosomes Cancer Date: 2014-03-28 Impact factor: 5.006
Authors: Liwen Hu; Yuanyuan Wu; Xingying Guan; Yan Liang; Xinyue Yao; Deli Tan; Yun Bai; Gang Xiong; Kang Yang Journal: Am J Cancer Res Date: 2015-09-15 Impact factor: 6.166
Authors: Andrea Y Angstadt; Terryl J Hartman; Samuel M Lesko; Joshua E Muscat; Junjia Zhu; Carla J Gallagher; Philip Lazarus Journal: Genes Chromosomes Cancer Date: 2014-06 Impact factor: 5.006
Authors: Deepak Kumar Bhatt; Abdul Basit; Haeyoung Zhang; Andrea Gaedigk; Seung-Been Lee; Katrina G Claw; Aanchal Mehrotra; Amarjit Singh Chaudhry; Robin E Pearce; Roger Gaedigk; Ulrich Broeckel; Timothy A Thornton; Deborah A Nickerson; Erin G Schuetz; John K Amory; J Steven Leeder; Bhagwat Prasad Journal: Drug Metab Dispos Date: 2018-03-30 Impact factor: 3.922